CT
CERE

ClearAlpha Technologies’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

ClearAlpha Technologies’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-149,438
Closed -$6.11M – 327
2024
Q2 		$6.11M Buy
149,438
+62,320
+72% +$2.6M 2.02% 11
2024
Q1 		$3.68M Buy
87,118
+51,732
+146% +$2.17M 1.55% 13
2023
Q4 		$1.5M Buy
+35,386
New +$1.02M 0.56% 41

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

ClearAlpha Technologies's CERE Position: Q3 2024 in Review

ClearAlpha Technologies sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 149,438 shares — an estimated $6.11M sold.

ClearAlpha Technologies first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $6.11M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • ClearAlpha Technologies reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • ClearAlpha Technologies sold 149,438 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $6.11M.
  • ClearAlpha Technologies first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • ClearAlpha Technologies's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $6.11M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on ClearAlpha Technologies's 13F filing for Q3 2024, filed 14 Nov 2024.